Fang Yuan, Qiu Qi, Zhang Shengyu, Sun Lin, Li Guanjun, Xiao Shifu, Li Xia
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, China.
Shanghai Key Laboratory of Forensic Medicine, Shanghai Forensic Service Platform, Institute of Forensic Science, Ministry of Justice, No. 1347, Guangfu West Road, Putuo District, Shanghai 200063, China.
J Affect Disord. 2018 Feb;227:745-751. doi: 10.1016/j.jad.2017.11.090. Epub 2017 Nov 21.
Neurotrophins including brain-derived neurotropic factor (BDNF) are implicated in the pathogenesis of major depressive disorder (MDD). Yet, the roles of brain-specific BDNF-related miRNAs miR-132 and miR-124 are unclear.
We enrolled 45 treatment-free patients with MDD, 32 citalopram-treated patients with MDD, and 32 healthy control subjects. Participants were assessed with the Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA). In a case-control sub-study, we followed 14 treatment-free patients who were subsequently treated with citalopram for 2 months. Enzyme-linked immunosorbent assay was used to detect plasma BDNF, and real-time polymerase chain reaction was used to quantify relative plasma miR-132 and miR-124 expression.
Patients with MDD had significantly higher HAMA and HAMD scores than the control group, with the highest scores in the treatment-free MDD group. Plasma miR-132 in the treatment-free MDD group was 2.4-fold that in the control group and significantly higher than that in the citalopram-treated MDD group. Plasma miR-124 in the treatment-free MDD and citalopram-treated MDD groups was 1.8-fold and 4-fold that in the control group, respectively. Compared to the control group, plasma BDNF levels were increased in both MDD groups, but not significantly different between them. There was a positive correlation between miR-132 and HAMD and HAMA scores, whereas no significant correlations were identified for plasma miR-124 or BDNF.
The range of neurotrophin-related MiRNAs and the number of follow-up cases were limited.
BDNF and miR-124 in plasma increase with depression and antidepressants. Plasma MiR-132 might be an indication for depression status.
包括脑源性神经营养因子（BDNF）在内的神经营养因子与重度抑郁症（MDD）的发病机制有关。然而，脑特异性BDNF相关的微小RNA miR-132和miR-124的作用尚不清楚。
我们招募了45名未接受治疗的MDD患者、32名接受西酞普兰治疗的MDD患者和32名健康对照者。参与者接受汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA）评估。在一项病例对照子研究中，我们跟踪了14名未接受治疗的患者，这些患者随后接受了2个月的西酞普兰治疗。采用酶联免疫吸附测定法检测血浆BDNF，并采用实时聚合酶链反应定量血浆miR-132和miR-124的相对表达。
MDD患者的HAMA和HAMD评分显著高于对照组，其中未接受治疗的MDD组评分最高。未接受治疗的MDD组血浆miR-132是对照组的2.4倍，显著高于接受西酞普兰治疗的MDD组。未接受治疗的MDD组和接受西酞普兰治疗的MDD组血浆miR-124分别是对照组的1.8倍和4倍。与对照组相比，两个MDD组的血浆BDNF水平均升高，但两组之间无显著差异。miR-132与HAMD和HAMA评分呈正相关，而血浆miR-124或BDNF未发现显著相关性。
神经营养因子相关微小RNA的范围和随访病例数有限。
血浆中的BDNF和miR-124随着抑郁和抗抑郁药治疗而增加。血浆miR-132可能是抑郁状态的一个指标。
